Vigil Neuroscience

Human brain
#Mergers and acquisitions #Neurodegenerative disorders #Neuroscience #Sanofi #Vigil Neuroscience

Sanofi completes acquisition of Vigil Neuroscience

Sanofi has completed its acquisition of Vigil Neuroscience, adding VG-3927, a novel, oral, small-molecule TREM2 agonist, to Sanofi’s neurology pipeline.  Vigil is a clinical-stage biotechnology company targeting neurodegenerative diseases through disease-modifying therapeutics that restore the vigilance of microglia.  Sanofi will also acquire Vigil’s preclinical pipeline… Read More

#Business & Investment #News